INCYTE CORP 4

Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp. (INCY), received grants of RSUs, performance shares, and stock options on July 16, 2026 as part of his equity compensation.

On July 16, 2026, Pablo J. Cagnoni, President and Global Head of R&D of Incyte Corp., received a package of equity compensation awards, including 13,403 shares of common stock in the form of restricted stock units, 33,508 performance share units that can pay out up to 200% of one share each based on three‑year relative TSR, and 57,861 employee stock options with a $116.65 exercise price that vest 25% after one year and monthly thereafter over three years. These are all reported as acquisitions (code “A”) and represent routine incentive grants rather than open‑market purchases or sales, increasing his derivative and non‑derivative equity exposure to the company, with 183,200 shares underlying unvested RSUs and earned performance units noted as outstanding after this grant.

Filing Facts

CIK

879169

Ticker

INCY

Form

4

Source Type

fda

Accession

0001205703-26-000021

Alert Tier

5